Current research toward optimizing dosing of first-line antituberculosis treatment

par McIlleron, Helen, Chirehwa, Maxwell T
Publié dans Expert Rev Anti Infect Ther (2018)

Quantitative assessment of the activity of antituberculosis drugs and regimens

par Chirehwa, Maxwell T., Velásquez, Gustavo E., Gumbo, Tawanda, McIlleron, Helen
Publié dans Expert Rev Anti Infect Ther (2019)

Use of the ‘Accountability for Reasonableness’ Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country

par Moosa, Mohammed Rafique, Maree, Jonathan David, Chirehwa, Maxwell T., Benatar, Solomon R.
Publié dans PLoS One (2016)

Correction: Use of the 'Accountability for Reasonableness' Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country

par Moosa, Mohammed Rafique, Maree, Jonathan David, Chirehwa, Maxwell T., Benatar, Solomon R.
Publié dans PLoS One (2016)

Quality of abstracts of pilot trials in heart failure: A protocol for a systematic survey

par Isiguzo, Godsent, Zunza, Moleen, Chirehwa, Maxwell, Mayosi, Bongani M., Thabane, Lehana
Publié dans Contemp Clin Trials Commun (2017)

Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study

par Dondo, Vongai, Mujuru, Hilda A, Nathoo, Kusum J, Chirehwa, Maxwell, Mufandaedza, Zivanai
Publié 2013

Quality of pilot trial abstracts in heart failure is suboptimal: a systematic survey

par Isiguzo, Godsent C., Zunza, Moleen, Chirehwa, Maxwell, Mayosi, Bongani M., Thabane, Lehana
Publié dans Pilot Feasibility Stud (2018)

Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

par Chirehwa, Maxwell T., Rustomjee, Roxana, Mthiyane, Thuli, Onyebujoh, Philip, Smith, Peter, McIlleron, Helen, Denti, Paolo
Publié dans Antimicrob Agents Chemother (2015)

Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

par Chirehwa, Maxwell T., Rustomjee, Roxana, Mthiyane, Thuli, Onyebujoh, Philip, Smith, Peter, McIlleron, Helen, Denti, Paolo
Publié dans Antimicrob Agents Chemother (2016)

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis

par Chirehwa, Maxwell T., McIlleron, Helen, Rustomjee, Roxana, Mthiyane, Thuli, Onyebujoh, Philip, Smith, Peter, Denti, Paolo
Publié dans Antimicrob Agents Chemother (2017)

Assessment of quality of obstetric care in Zimbabwe using the standard primipara

par Guzha, Bothwell Takaingofa, Magwali, Thulani Lesley, Mateveke, Bismark, Chirehwa, Maxwell, Nyandoro, George, Munjanja, Stephen Peter
Publié dans BMC Pregnancy Childbirth (2018)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

par Rockwood, Neesha, Meintjes, Graeme, Chirehwa, Maxwell, Wiesner, Lubbe, McIlleron, Helen, Wilkinson, Robert J., Denti, Paolo
Publié dans Antimicrob Agents Chemother (2016)

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

par Chirehwa, Maxwell T, McIlleron, Helen, Wiesner, Lubbe, Affolabi, Dissou, Bah-Sow, Oumou, Merle, Corinne, Denti, Paolo
Publié dans J Antimicrob Chemother (2019)

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis

par Ghafari, Nazanin, Court, Richard, Chirehwa, Maxwell Tawanda, Wiesner, Lubbe, Petersen, Lucretia, Maartens, Gary, Gumbo, Tawanda, McIlleron, Helen, Ramma, Lebogang
Publié dans Int J Audiol (2019)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

par Court, Richard, Centner, Chad M., Chirehwa, Maxwell, Wiesner, Lubbe, Denti, Paolo, de Vries, Nihal, Harding, Joseph, Gumbo, Tawanda, Maartens, Gary, McIlleron, Helen
Publié dans Int J Infect Dis (2021)

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB

par Naidoo, Anushka, Chirehwa, Maxwell, McIlleron, Helen, Naidoo, Kogieleum, Essack, Sabiha, Yende-Zuma, Nonhlanhla, Kimba-Phongi, Eddy, Adamson, John, Govender, Katya, Padayatchi, Nesri, Denti, Paolo
Publié dans J Antimicrob Chemother (2017)

Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone

par Chirehwa, Maxwell T., Court, Richard, de Kock, Mariana, Wiesner, Lubbe, de Vries, Nihal, Harding, Joseph, Gumbo, Tawanda, Maartens, Gary, Warren, Rob, Denti, Paolo, McIlleron, Helen
Publié dans Antimicrob Agents Chemother (2020)

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis

par Naidoo, Anushka, Ramsuran, Veron, Chirehwa, Maxwell, Denti, Paolo, McIlleron, Helen, Naidoo, Kogieleum, Yende-Zuma, Nonhlanhla, Singh, Ravesh, Ngcapu, Sinaye, Chaudhry, Mamoonah, Pepper, Michael S, Padayatchi, Nesri
Publié dans Pharmacogenomics (2018)

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis

par Naidoo, Anushka, Chirehwa, Maxwell, Ramsuran, Veron, McIlleron, Helen, Naidoo, Kogieleum, Yende-Zuma, Nonhlanhla, Singh, Ravesh, Ncgapu, Sinaye, Adamson, John, Govender, Katya, Denti, Paolo, Padayatchi, Nesri
Publié dans Pharmacogenomics (2019)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis

par Schutz, Charlotte, Chirehwa, Maxwell, Barr, David, Ward, Amy, Janssen, Saskia, Burton, Rosie, Wilkinson, Robert J., Shey, Muki, Wiesner, Lubbe, Denti, Paolo, McIlleron, Helen, Maartens, Gary, Meintjes, Graeme
Publié dans Br J Clin Pharmacol (2020)